Detalles de la búsqueda
1.
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pharmacoeconomics
; 40(8): 777-790, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35696071
Resultados
1 -
1
de 1
1
Próxima >
>>